태터데스크 관리자

도움말
닫기
적용하기   첫페이지 만들기

태터데스크 메시지

저장하였습니다.

카테고리 없음2020. 4. 2. 17:08
Loading

30개국 의사6200여명 설문조사 코로나19처방 1위는 진통제, 2위는 아지스로마이신, 3위는 하이드록시클로로퀸

출처  https://www.washingtontimes.com/news/2020/apr/2/hydroxychloroquine-rated-most-effective-therapy-do/

https://public-cdn.sermo.com/covid19/c8/be4e/4edbd4/dbd4ba4ac5a3b3d9a479f99cc5/wave-i-sermo-covid-19-global-analysis-final.pdf

 

Hydroxychloroquine rated ‘most effective therapy’ by doctors for coronavirus: Global survey

An international poll of more than 6,000 doctors released Thursday found that the antimalarial drug hydroxychloroquine was the most highly rated treatment for the novel coronavirus.

www.washingtontimes.com

Treatments & Efficacy:

• 3 most commonly prescribed treatments amongst COVID-19 treaters are 56% analgesics, 41% Azithromycin, and 33% Hydroxychloroquine.

• Hydroxychloroquine usage amongst COVID-19 treaters is 72% in Spain, 49% in Italy, 41% in Brazil, 39% in Mexico, 28% in France, 23% in US, 17% in Germany, 16% in Canada, 13% in UK and 7% in Japan.

• Hydroxychloroquine was overall chosen as the most effective therapy from a list of 15 options (37% of COVID-19 treaters). • 75% in Spain, 53% Italy, 44% in China, 43% in Brazil, 29% in France, 23% in US and 13% in UK.

• The two most common treatment regimens for Hydroxychloroquine were: • (38%) 400mg twice daily on day one; 400 mg daily for 5 days. • (26%) 400mg twice daily on day one; 200mg twice daily for 4 days.

• Outside the US, Hydroxychloroquine was equally used for diagnosed patients with mild to severe symptoms whereas in the US it was most commonly used for high risk diagnosed patients.

• Globally, 19% of physicians prescribed or have seen Hydroxychloroquine prophylactically used for high risk patients, and 8% for low risk patients

 

Hydroxychloroquine rated ‘most effective therapy’ by doctors for coronavirus: Global survey

An international poll of more than 6,000 doctors released Thursday found that the antimalarial drug hydroxychloroquine was the most highly rated treatment for the novel coronavirus.

www.washingtontimes.com